Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07231029
PHASE1
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Sponsor: Taisho Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment
Official title: An Open-label Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-12-23
Completion Date
2026-10-31
Last Updated
2026-01-09
Healthy Volunteers
No
Interventions
DRUG
TS-172
Single oral administration of TS-172 20mg
Locations (1)
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan